Evidence map›Paper›PMID 28527771›Full record

Trial reportJACC. Cardiovascular interventions2017

Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomized Clinical Trial.

Josep Rodés-Cabau, Jean-Bernard Masson, Robert C Welsh, Bruno Garcia Del Blanco, Marc Pelletier, John G Webb, Faisal Al-Qoofi, Philippe Généreux, Gabriel Maluenda, Martin Thoenes and 5 more

2 registry-linked trialsAbstract readComparative StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in JACC. Cardiovascular interventions, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 105 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
105citing papers in PubMed, 12 pooled it
26.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01559298 phase4completednot on this map

Aspirin Versus Aspirin + ClopidogRel as Antithrombotic Treatment Following Transcatheter Aortic Valve Implantation With the Edwards SAPIEN XT Valve. A Randomized Pilot Study (the ARTE Trial)

TypeinterventionalSponsorCentre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de QuebecRan2012 to 2016Enrolled178ConditionsAortic Valve Disease, Myocardial Infarction, StrokeArmsAspirin (80 mg/d) + clopidogrel (75 mg/d), Aspirin
NCT02640794 phase4completednot on this map

Aspirin Versus Aspirin + ClopidogRel as Antithrombotic Treatment Following Transcatheter Aortic Valve Implantation With the Edwards Valve. A Randomized Study (the ARTE Trial)

TypeinterventionalSponsorCentre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de QuebecRan2015 to 2018Enrolled222ConditionsAortic Valve Disease, Myocardial Infarction, Stroke, BleedingArmsClopidogrel, Aspirin
3 · Its place in the literature

Who cites it

105 citing papers in PubMed, 12 syntheses or guidelines pooled it, 327 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Understanding Aortic Stenosis and Transcatheter Aortic Valve Replacement in Women.Structural heart : the journal of the Heart Team · 2025
    Review

45 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 10 institutions in 5 countries.

Josep Rodés-CabauQuebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada. Electronic address: josep.rodes@criucpq.ulaval.ca.
Jean-Bernard MassonCentre Hospitalier de l'Université de Montreal, Montreal, Quebec, Canada.
Robert C WelshMazankowski Alberta Heart Institute and University of Alberta, Edmonton, Alberta, Canada.
Bruno Garcia Del BlancoHospital Universitari Vall d'Hebron, Barcelona, Spain.
Marc PelletierSaint John's Regional Hospital, Saint John, New Brunswick, Canada.
John G WebbSt. Paul's Hospital, Vancouver, British Columbia, Canada.
Faisal Al-QoofiFoothills Hospital, Calgary, Alberta, Canada.
Philippe GénéreuxHôpital du Sacré-Coeur de Montreal, Montreal, Quebec, Canada.
Gabriel MaluendaHospital San Borja Arriaran, Santiago de Chile, Chile.
Martin ThoenesLéman Research Institute, Geneva, Switzerland.
Jean-Michel ParadisQuebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada.
Chekrallah ChamandiQuebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada.
Vicenç SerraHospital Universitari Vall d'Hebron, Barcelona, Spain.
Eric DumontQuebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada.
Mélanie CôtéQuebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada.
Université Laval · CAVall d'Hebron Hospital Universitari · ESCentre Hospitalier de l’Université de Montréal · CAHôpital du Sacré-Cœur de Montréal · CAHospital San Borja Arriarán · CLLeman University · CHLung Institute · USSaint John Regional Hospital · CASt. Paul's Hospital · CAUniversity of Alberta · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe aim of this study was to compare aspirin plus clopidogrel with aspirin alone as antithrombotic treatment following transcatheter aortic valve replacement (TAVR) for the prevention of ischemic events, bleeding events, and death.

backgroundFew data exist on the optimal antithrombotic therapy following TAVR.

methodsThis was a randomized controlled trial comparing aspirin (80 to 100 mg/day) plus clopidogrel (75 mg/day) (dual antiplatelet therapy [DAPT]) versus aspirin alone (single-antiplatelet therapy [SAPT]) in patients undergoing TAVR with a balloon-expandable valve. The primary endpoint was the occurrence of death, myocardial infarction (MI), stroke or transient ischemic attack, or major or life-threatening bleeding (according to Valve Academic Research Consortium 2 definitions) within the 3 months following the procedure. The trial was prematurely stopped after the inclusion of 74% of the planned study population.

resultsA total of 222 patients were included, 111 allocated to DAPT and 111 to SAPT. The composite of death, MI, stroke or transient ischemic attack, or major or life-threatening bleeding tended to occur more frequently in the DAPT group (15.3% vs. 7.2%, p = 0.065). There were no differences between groups in the occurrence of death (DAPT, 6.3%; SAPT, 3.6%; p = 0.37), MI (DAPT, 3.6%; SAT, 0.9%; p = 0.18), or stroke or transient ischemic attack (DAPT, 2.7%; SAPT, 0.9%; p = 0.31) at 3 months. DAPT was associated with a higher rate of major or life-threatening bleeding events (10.8% vs. 3.6% in the SAPT group, p = 0.038). There were no differences between groups in valve hemodynamic status post-TAVR.

conclusionsThis small trial showed that SAPT (vs. DAPT) tended to reduce the occurrence of major adverse events following TAVR. SAPT reduced the risk for major or life-threatening events while not increasing the risk for MI or stroke. Larger studies are needed to confirm these results. (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation: The ARTE Trial [ARTE], NCT01559298; Aspirin Versus Aspirin+Clopidogrel as Antithrombotic Treatment Following TAVI [ARTE], NCT02640794).

Indexed as

Balloon ValvuloplastyHeart Valve ProsthesisAgedAged, 80 and overAortic ValveAspirinCanadaClopidogrelDrug Therapy, CombinationEarly Termination of Clinical TrialsEuropeFemaleFibrinolytic AgentsHemorrhageHumansIschemic Attack, TransientAspirinClopidogrelFibrinolytic AgentsPlatelet Aggregation InhibitorsTiclopidineaortic stenosisaspirinbleedingclopidogrelstroketranscatheter aortic valve replacement

Identifiers

PMID28527771
OpenAlexW2614453373

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.